Key Pharmaceutical Shift: India Ministry Proposes Rationalizing Drug Shelf-Life Rules to Boost Global Trade and Supply Chain Efficiency

Key Pharmaceutical Shift: India Ministry Proposes Rationalizing Drug Shelf-Life Rules to Boost Global Trade and Supply Chain Efficiency​

Draft Amendment Aims to Ease Business in Pharma Sector​

The Union Ministry of Health and Family Welfare has initiated a major regulatory review concerning the residual shelf-life requirements for imported drugs. The ministry published a draft notification proposing amendments to Rule 31 of the Drugs Rules, 1945. This move is explicitly aimed at rationalizing these requirements and promoting greater Ease of Doing Business within India's pharmaceutical sector.

The proposed changes seek to streamline the importation process without compromising the quality or availability of essential medicines for patients. By revising existing standards, the government aims to significantly improve operational efficiency across the entire supply chain.

Revisions Proposed: From Percentage Requirement to 12-Month Minimum​

Currently, there is a restrictive requirement that imported drugs must maintain a minimum residual shelf life exceeding 60 per cent at the time of import. The draft amendment seeks to revise this standard substantially.

The proposal suggests setting a new minimum requirement of 12 months residual shelf life for most imported drugs upon entry into the country. This adjustment is intended to ensure sufficient distribution and consumption time before any medicines reach their expiry date.

Mitigating Wastage and Optimizing Inventory​

This rationalization is expected to yield immediate benefits for the pharmaceutical industry. By setting a clear minimum standard, the amendment aims to reduce avoidable wastage of medicines that arises from overly restrictive existing requirements.

Improving inventory utilization across various supply chain levels is a primary goal. The revised regulation is set to optimize supply management and subsequently contribute to lower costs associated with medicine importation and distribution within India.

Exceptions for Specialised Medicines Explained​

While the broad change facilitates greater efficiency, the Ministry has maintained specific safeguards for critical categories of medication. Biological products and radiopharmaceuticals will remain subject to the existing stringent requirement.

These specialised drugs must still meet the previous standard of having a minimum residual shelf life exceeding 60 per cent at the time of import. This distinction ensures that public health considerations are thoroughly addressed for high-sensitivity medical items.

Regulatory Clarification and Stakeholder Feedback Invited​

The Ministry has issued clear clarifications regarding the scope of this amendment. It is crucial to understand that the proposed changes pertain exclusively to the residual shelf-life requirement applicable at the point of import.

The draft notification does not alter any other existing regulatory obligations concerning the quality, safety, or efficacy of medicines under the Drugs and Cosmetics Act, 1940, nor the Drugs Rules, 1945.

All interested stakeholders are invited to review the draft notification and submit objections and suggestions. Comments can be submitted through the specified channels provided by the Ministry of Health and Family Welfare.